Compare MDGL & BILI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDGL | BILI |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 12.1B |
| IPO Year | N/A | 2018 |
| Metric | MDGL | BILI |
|---|---|---|
| Price | $476.87 | $31.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 7 |
| Target Price | ★ $631.46 | $30.00 |
| AVG Volume (30 Days) | 302.4K | ★ 3.6M |
| Earning Date | 02-19-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | $740,640,000.00 | ★ $4,180,323,637.00 |
| Revenue This Year | $435.42 | $14.70 |
| Revenue Next Year | $54.39 | $9.45 |
| P/E Ratio | ★ N/A | $120.88 |
| Revenue Growth | ★ 864.21 | 16.95 |
| 52 Week Low | $265.00 | $14.47 |
| 52 Week High | $615.00 | $36.40 |
| Indicator | MDGL | BILI |
|---|---|---|
| Relative Strength Index (RSI) | 39.22 | 49.96 |
| Support Level | $458.00 | $30.38 |
| Resistance Level | $486.88 | $31.56 |
| Average True Range (ATR) | 19.28 | 1.01 |
| MACD | 0.70 | -0.58 |
| Stochastic Oscillator | 40.73 | 24.90 |
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Bilibili is a Chinese online entertainment platform best known for its YouTube-like video-sharing site. Founded in 2009, it initially focused on long-form content centered around anime, comics, and gaming, catering primarily to Gen Z users. Over time, the platform has broadened its content offerings to include a wider range of interests, successfully attracting a more diverse audience beyond the Gen Z demographic.